Kamyar Kalantar-Zadeh M.D. to Ergocalciferols
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Ergocalciferols.
Connection Strength
3.311
-
The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD. J Med Econ. 2020 Mar; 23(3):308-315.
Score: 0.651
-
Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients. J Ren Nutr. 2016 07; 26(4):265-9.
Score: 0.504
-
Clinical uses of 1-alpha-hydroxy-ergocalciferol. Curr Vasc Pharmacol. 2014 Mar; 12(2):306-12.
Score: 0.436
-
Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1232-9.
Score: 0.395
-
Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis. 2012 Jan; 59(1):58-66.
Score: 0.367
-
Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008 Nov; 3(6):1769-76.
Score: 0.297
-
Survival differences between activated injectable vitamin D2 and D3 analogs. Kidney Int. 2007 Apr; 71(8):827; author reply 827-8.
Score: 0.270
-
Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol. 2010; 32(5):403-13.
Score: 0.086
-
Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010 Aug; (117):S10-21.
Score: 0.085
-
Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol. 2008; 40(2):427-40.
Score: 0.071
-
Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr. 2007 Jan; 17(1):38-44.
Score: 0.066
-
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006 Aug; 70(4):771-80.
Score: 0.064
-
Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb; 14(1):18-27.
Score: 0.018